Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Polycythemia Vera

Conditions

Polycythemia Vera

Trial Timeline

Jul 1, 2015 → Dec 1, 2015

NCT ID

NCT02523638

About Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen

Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen is a phase 3 stage product being developed by PharmaEssentia for Polycythemia Vera. The current trial status is completed. This product is registered under clinical trial identifier NCT02523638. Target conditions include Polycythemia Vera.

What happened to similar drugs?

2 of 16 similar drugs in Polycythemia Vera were approved

Approved (2) Terminated (1) Active (14)

✅HydroxyureaNovartisApproved

✅Ropeginterferon alfa-2bPharmaEssentiaApproved

🔄Sapablursen + PlaceboOno PharmaceuticalPhase 3

🔄Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3

🔄ruxolitinib tabletsNovartisPhase 3

🔄RuxolitinibNovartisPhase 3

🔄Best Available Therapy + RuxolitinibNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02523638	Phase 3	Completed	Jul 1, 2015	Dec 1, 2015	Polycythemia Vera

Competing Products

20 competing products in Polycythemia Vera

See all competitors

Product	Company	Stage	Hype Score
Sapablursen + Placebo	Ono Pharmaceutical	Phase 3	47
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Bomedemstat	Merck	Phase 2	35
Ruxolitinib + Hydroxycarbamide + Interferon-Alpha	Novartis	Phase 3	47
ruxolitinib tablets	Novartis	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Ruxolitinib	Novartis	Phase 3	40
Ruxolitinib + BAT	Novartis	Phase 2	39
Hydroxyurea	Novartis	Approved	35
Best Available Therapy + Ruxolitinib	Novartis	Phase 3	40
Smac Mimetic LCL161	Novartis	Phase 2	35
PEGASYS + Aspirin	Roche	Phase 2	35
RG7388 + Pegasys	Roche	Phase 1	29
Idasanutlin	Roche	Phase 2	27
PEGASYS + Hydroxyurea + Aspirin	Roche	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Phase 2	39
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)	PharmaEssentia	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Approved	50
P1101 + Low-dose aspirin	PharmaEssentia	Phase 2	35
P1101 (Ropeginterferon alfa-2b)	PharmaEssentia	Phase 3	47